Skip to main content
U.S. flag

An official website of the United States government

Milestone 2.L

AD Related Dementias – Specific

Advance basic and clinical research on common mechanisms of multi-etiology cognitive impairment and dementia.

Success Criteria

  • Initiate at least one new funding opportunity announcement that promotes understanding of interactions among different pathologies of dementia, e.g. beta-amyloidosis, 3R/4R tauopathy, 4R tauopathy, TDP-43, alpha-synucleinopathy, arteriolosclerosis and other cerebrovascular diseases, as well as other neurodegenerative processes such as TBI or prion diseases.
  • Support research in general and diverse U.S. populations focused on identifying molecular pathways that, during aging, either accelerate cognitive decline or protect against cognitive decline and non-cognitive but related symptoms such as gait impairment or physical frailty. This research should be designed to further develop and optimize biomarkers of age-related cognitive impairment and dementia for clinical trials, clinical research, and toward general clinical use.
  • Develop research nomenclature for dementia that can clearly and accurately communicate the emerging scientific understanding of multiple etiology dementias both in research and in clinical practice.

Summary of Key Accomplishments

In FY18 and FY19, NIH released funding opportunities on common mechanisms of AD/ADRD (PAS-17-028) and to identify new potential clinical targets (PAR-18-661) that can detect characteristics of AD vs. ADRDs as compared to healthy individuals. One award is describing, at a cellular level, molecular signatures of AD, LBD, FTD and healthy individuals, and researchers have published promising, initial results. NINDS also funds the “Center Without Walls for Imaging Proteinopathies with PET,” which is developing novel, sophisticated technology to visualize and differentiate several different AD- and ADRD-related brain changes. The Dementia Nomenclature Initiative continues to work on developing consistent, accurate, and meaningful language for cognitive impairment and dementia, including how best to describe and communicate the difference between multiple etiology dementia and other versions of AD/ADRDs.

This information is current as of July 2022.

Research Implementation Area
AD Related Dementias - Specific
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

An official website of the National Institutes of Health